‘Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology [Yahoo! Finance]
ASX LTD UNSP/ADR (ASXFY)
NASDAQ:AMEX Investor Relations:
asx.com.au/about/investor-relations.htm
Company Research
Source: Yahoo! Finance
results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET agent, TLX250-CDx (Zircaix® Zr-girentuximab), is highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs). In this peer-reviewed manuscript, Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues report results from this prospective, open-label, multicentre, Phase III trial in which 300 patients with an IRM =7cm (cT1) received TLX250-CDx. Authors conclude that TLX250-CDx “has a favorable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterization of ccRCC, which has the potential to be practice changing.” Authors explain that small masses in the kidney are increasingly being detected incidentally when patients undergo abdominal imaging, often for other health conditions, contributing
Show less
Read more
Impact Snapshot
Event Time:
ASXFY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASXFY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASXFY alerts
High impacting ASX LTD UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ASXFY
News
- Max Resource Provides Update on its Florália Hematite Iron Ore Project, Mina Gerais State, Brazil [Yahoo! Finance]Yahoo! Finance
- Institutional investors in ASX Limited (ASX:ASX) lost 5.0% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- CleanTech Lithium PLC Announces Interim Results [Yahoo! Finance]Yahoo! Finance
- Australia's Beston Global enters voluntary administration [Yahoo! Finance]Yahoo! Finance
- Our Pick Of The Best Oil Stocks For Australians [Forbes]Forbes